Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Informazioni relative al progetto

ExitAplasia

ID dell’accordo di sovvenzione: 827629

DOI

10.3030/827629

Progetto chiuso

Data della firma CE 9 Agosto 2018

Data di avvio 1 Novembre 2018

Data di completamento 30 Aprile 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

REGSTEM
France

Periodic Reporting for period 1 - ExitAplasia (Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies)

Periodo di rendicontazione: 2018-11-01 al 2019-04-30

Sintesi del contesto e degli obiettivi generali del progetto

Some cancers, like leukaemia or cancers of some solid organs, need particularly aggressive treatments: heavy chemotherapy, alone or associated with radiotherapy (total body irradiation).
These treatments induce “aplasia”: the bone marrow doesn’t produce cells for the bloodstream anymore; these cells are well known and crucial for life: red cells (oxygen transport), white cells (immune defense against infection, bacteria, viruses), and platelets (to prevent bleeding after injuries).
These patients can be very young and even child can be concerned.
This aplasia has to be transient: it is a very serious condition which leads to death if it lasts too long; after a few days, the patients usually recover from aplasia, but meanwhile, they can suffer from uncontrolled infection or life-threatening bleeding.
Thus, the longer is aplasia, the higher is the risk of death for the patients. And the patients who do not succeed in recover from aplasia die.

We invented a mean to shorten this aplasia, increase the rate and speed of recovery from it. We are currently designing new drugs to specifically shorten it and increase the chance of survival for these patients.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

We designed new chemical molecules and synthesize them ; we did some preliminary experiments in laboratory to check that they could be good candidates for future efficient medicines for patients.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We expect to find a new molecule that could become a marketed drug for patients who suffer from aplasia. This would save patients, which is obviously our primary goal.
It would also strongly shorten the lenght and consistenly decrease the cost of hospitalization. Thus, the financial burden of the concerned diseases would also be significantly decreased.

Illustration of kind of patient concerned (actress !)